Keywords: Bristol-Myers Squibb, Pharmasset, Hepatitit C, Research, BMS-790052, PSI-7977
Bristol-Myers Squibb collaborates with Pharmasset on combo hep C drug trial
Article | 11 January 2011
US drug major Bristol-Myers Squibb (NYSE: BMY) has entered into a clinical collaboration agreement to evaluate its utility of BMS-790052, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
